CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
Cabozantinib (XL184)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01866293
NCT01866293Phase 2Completed
CompareCT.gov

A Phase I/II Trial of Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma

Memorial Sloan Kettering Cancer Center·interventional·Posted May 31, 2013·Updated Aug 30, 2017

In Brief

A Phase 2 clinical trial evaluating Cabozantinib (XL184) for Relapsed or Refractory Multiple Myeloma. Completed, enrolled 11 participants across 5 sites.

Detailed Summary

This study is an open label phase I/II trial to investigate the safety and efficacy of Cabozantinib for patients with relapsed or refractory myeloma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsed or Refractory Multiple Myeloma
CountriesUnited States
CollaboratorsExelixis

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMay 31, 2013
Enrollment StartMay 28, 2013
Primary CompletionAug 18, 2016
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 13.1 years ago

Interventions

Cabozantinib (XL184)drug